BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Regor’s Oral GLP-1RA RGT-075 Shows 5% Placebo-Adjusted Weight Loss in Phase 2a Trial with Strong Safety Profile

Regor announced its 12-week single-dose Phase 2a trial results for RGT-075, a once-daily oral GLP-1RA, reporting 5% placebo-adjusted weight-loss with no ...

January 13, 2025 | News

Glooko and Hedia Launch Interoperable Solution for Advanced Diabetes Management in the UK

Glooko, Inc. and Hedia, announced the launch of their interoperable solution, which combines connected care, remote patient monitoring, and digital th...

January 09, 2025 | News

Health2Sync's Vision for Diabetes Care: Transforming Outcomes Through Technology and Partnerships

In an exclusive interview with BioPharma APAC, Ed Deng, Co-founder and CEO of Health2Sync, delves into the transformative impact of their collabora...

December 24, 2024 | Interaction

Taiwan’s Health2Sync Partners with Western Sydney Diabetes to Transform Diabetes Care Through Digital Innovation

Health2Sync, Asia’s leading digital health solutions provider, announced a new partnership with Western Sydney Diabetes . This collaboration aims to ...

December 18, 2024 | News

Eli Lilly Announces $3 Billion Expansion in Wisconsin to Boost Global Medicine Production

The investment will benefit millions of patients worldwide, boosting the production of the company's medicines, including those for diabetes and obesity&nb...

December 06, 2024 | News

OPTIMUM Tele-Monitoring System Demonstrates Significant Health Gains in Type 2 Diabetes Care in Singapore

A cutting-edge tele-monitoring system, OPTIMUM (Optimising care of Patients via Telemedicine In Monitoring and Augmenting their control of Diabetes Mellitu...

November 12, 2024 | News

Diabetes Singapore and GSK Strengthen Efforts to Tackle Rising Viral Infection Risks in Diabetes Care

Diabetes Singapore and GSK aim to enhance awareness and improve lives affected by diabetes through educational talks and activities on World Di...

November 12, 2024 | News

Hong Kong Approves Eli Lilly’s Mounjaro® as First Dual-Receptor Agonist for Obesity and Type 2 Diabetes

Adults taking Mounjaro in a clinical trial lost on average 48 lb. at the highest dose1,2 Mounjaro delivered superior A1C reductions versus all comparato...

October 28, 2024 | News

Endogenex Achieves Key Clinical Milestone with First Patient Enrolled in ReCET™ Study for Type 2 Diabetes Treatment

Achieving a Significant Clinical Milestone in Assessing the ReCET™ System as a Groundbreaking Treatment for Type 2 Diabetes Endogenex, Inc., a clini...

October 16, 2024 | News

HighTide Therapeutics Presents Promising Data on HTD1801 for Type 2 Diabetes at EASD 2024

HighTide Therapeutics, Inc. (2511.HK), a clinical-stage biopharmaceutical company dedicated to developing multifunctional therapies for chronic liver and m...

September 12, 2024 | News

Yunovia Gains MFDS Clearance for Phase 1 MAD Study of Oral GLP-1 Agonist for Diabetes and Obesity

Yunovia, a drug R&D subsidiary of Ildong Pharmaceutical Group, announced on the 26th that the Ministry of Food and Drug Safety (MFDS) of Korea has clea...

August 28, 2024 | News

FDA Expands Approval of Insulet SmartAdjust Technology to Include Type 2 Diabetes Management

U.S. Food and Drug Administration expanded the indications of the Insulet SmartAdjust technology, an interoperable automated glycemic controller previously...

August 27, 2024 | News

AiViva Biopharma Completes Enrollment in Phase 1 Trial of AIV007 for Wet AMD and DME

AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that it has fully enrolled and completed dosing the last patient in a Phase 1 tria...

August 26, 2024 | News

Sanyou Bio and JiAnTeBo Forge Strategic Partnership to Innovate Metabolic Disease Therapies

Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "Sanyou Bio") and Guangdong JiAnTeBo Biotechnology Co., Ltd. (hereinafter r...

August 08, 2024 | News

Stay Connected